Notably, combining L14‐8 with low dosages of AR antagonists, such as enzalutamide and darolutamide, significantly enhanced their anti‐tumor activity in the AR‐positive prostate cancer cell models (Figure S2, Supporting Information). Here, AR is linked to neoplasm.